ERBB2 and breast carcinoma: Regarding prognostic profiles, our study revealed a great heterogeneity associated with HR expression in HER2-positive breast cancer, of which the HR + expression was in line with the mortality decrease of both OS and BCSS and this kind of correlation was inherently stable.